Lacosamide: New adjunctive treatment option for partial-onset seizures

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1595-1602

  Chung, Steve S ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Lacosamide; New anticonvulsant; Partial seizures; Slow inactivation; Sodium channels; Vimpat

Indexed keywords

CARBAMAZEPINE; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHOSUXIMIDE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; LIVER ENZYME; METFORMIN; OMEPRAZOLE; PHENYTOIN; VALPROIC ACID;

ADJUVANT THERAPY; BLURRED VISION; BODY WEIGHT; CLINICAL TRIAL; CLONIC SEIZURE; COMPLEX PARTIAL SEIZURE; CONVULSION; COORDINATION DISORDER; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FOCAL EPILEPSY; GOVERNMENT REGULATION; HEADACHE; HUMAN; INJECTION SITE PAIN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; TREMOR; VERTIGO; VOMITING;

ACETAMIDES; ANTICONVULSANTS; EPILEPSY; HUMANS; TREATMENT OUTCOME;

EID: 77952727105     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.488639     Document Type: Review

References (34)

1. Centers for Disease Control and Prevention. Prevalence of self-reported epilepsy--United States, 1986 - 1990. JAMA 1994;272(24):1893
2. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007;16:296-304
3. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319
4. Perucca E. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804
5. Andurkar SV, Stables JP, Kohn H. The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 1999;7:2381-2389
6. Hovinga CA. SPM-927 (Schwarz Pharma). IDrugs 2003;6:479-485
7. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:21-42
8. St€ohr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74:147-154
9. Brandt C, Heile A, Potschka H, et al. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006;47:1803-1809
10. Errington AC, St€ohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2006;3:157-169
11. Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927 [abstract]. Epilepsia 2002;43:188
12. Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927 [abstract]. Epilepsia 2004;45:307
13. Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 2007;4:145-218
14. Thomas D, Scharfenecker U, Nickel B, et al. Low potential for drug--drug interaction of lacosamide [abstract]. Epilepsia 2006;47:200
15. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on the new antiepileptic drugs: a summary of the eigth eilat conference (EILAT VIII). Epilepsy Res 2007;73:1-52
16. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 2008;44:35-40
17. U.S. Food and Drug Administration. Vimpat (lacosamide) tablets and injection: US prescribing information. Available from: http://www.fda.gov/cder/ foi/label/2008/022253lbl.pdf. [Last accessed 30 October 2008]
18. European Medicines Agency. Lacosamide (Vimpat): summary of product characteristics. Available from: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/vimpat/H-863-PI-en.pdf. [Last accessed 5 November 2008]
19. Beydoun A, D'souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33-42
20. Kropeit D, Schiltmeyer B, Cawello W, et al. Bioequivalence of short-time infusions compared to oral administration of SPM 927 [abstract]. Epilepsia 2004;45:123
21. Bialer M, Johannessen S, Levy R, et al. Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43
22. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-1317
23. Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-453
24. Chung S, Sperling M, Biton V, et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 2010. [Epub ahead of print]
25. Wehner T, Bauer S, Hamer HM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16:423-425
26. Rosenfeld W, Fountaine N, Kaubrys G, et al.. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjuctive therapy in subjects with partialonset seizures [abstract]. Epilepsia 2007;48:318
27. Kennebäck G, Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther 1995;9:709-714
28. Kennebäck G, Bergfeldt L, Vallin H, et al. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121:1421-1429
29. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-2291
30. Laville MA, de la Gastine B, Husson B, et al. Should we care about pregabalin for elderly patients with a history of cardiac dysrhythmia? Rev Med Interne 2008;29:152-154
31. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008;49:418-424
32. Krauss G, Ben Menachem E, Mameniskiene R, et al. Lacosamide: safety and tolerability of adjunctive intravenous lacosamide as short-term replacement for oral lacosamide in subjects with partial-onset seizures during 30-, 15-, and 10-minute infusions. Eur J Neurol 2007;14:319-320
33. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009;14:429-431
34. Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by parenteral lacosamide. Epilepsia 2010;51:316-317